Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical Jun 30, 2026 7:32pm EDT
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation Jun 15, 2026 7:30am EDT
Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical May 29, 2026 7:30am EDT
Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical Apr 30, 2026 7:30am EDT
Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights Mar 31, 2026 5:22pm EDT
Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement Mar 23, 2026 7:30am EDT
Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical Mar 19, 2026 7:30am EDT
Aptose Biosciences Announces Amendment to Arrangement Agreement and Details of Postponed Special Meeting of Shareholders Feb 24, 2026 7:00am EST
Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC Dec 19, 2025 5:05pm EST
